Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck on Thursday topped third-quarter estimates and hiked its adjusted profit outlook, as its immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales. 

Th...